PVR--IMMUNOPHARMACOLOGICAL APPROACH TO TREATMENT

Information

  • Research Project
  • 2162623
  • ApplicationId
    2162623
  • Core Project Number
    R43EY009021
  • Full Project Number
    1R43EY009021-01A1
  • Serial Number
    9021
  • FOA Number
  • Sub Project Id
  • Project Start Date
    9/1/1991 - 33 years ago
  • Project End Date
    6/30/1992 - 32 years ago
  • Program Officer Name
  • Budget Start Date
    9/1/1991 - 33 years ago
  • Budget End Date
    6/30/1992 - 32 years ago
  • Fiscal Year
    1991
  • Support Year
    1
  • Suffix
    A1
  • Award Notice Date
    8/20/1991 - 33 years ago

PVR--IMMUNOPHARMACOLOGICAL APPROACH TO TREATMENT

DESCRIPTION: (Investigator's Abstract) Proliferative vitreoretinopathy (PVR) is a potentially blinding disease caused by the migration into and subsequent proliferation of retinal pigmented epithelial cells (RPE), glial cells, fibroblasts and macrophages in the vitreous cavity. This invasion of the vitreous can result from disease or trauma. Growth and differentiation of the invading cells can eventually lead to a tractional distortion and detachment of the retina. The proposed research seeks to develop monoclonal antibody-based immunotoxins specific for these offending cells. The resulting immunotoxin(s) could be used at the time of vitreal-retinal surgery as a preventive, or as a treatment to prevent further growth of the invading cells, and hence eliminate the need for vitreal retinal surgery, or as an adjunct to surgery. It would be particularly useful in cases of posterior segment penetrating injury, which is a major cause of PVR. The major objectives of the Phase I application are to prepare cell specific monoclonal antibodies, to determine their potential as immunotoxins in in vitro assays, and to establish an in vitro model for PVR. The objective of the phase II application would be to test these immunotoxins in vivo for efficacy and toxicity.

IC Name
NATIONAL EYE INSTITUTE
  • Activity
    R43
  • Administering IC
    EY
  • Application Type
    1
  • Direct Cost Amount
  • Indirect Cost Amount
  • Total Cost
  • Sub Project Total Cost
  • ARRA Funded
  • CFDA Code
    867
  • Ed Inst. Type
  • Funding ICs
  • Funding Mechanism
  • Study Section
    VISB
  • Study Section Name
    Visual Sciences B Study Section
  • Organization Name
    HOUSTON BIOTECHNOLOGY, INC.
  • Organization Department
  • Organization DUNS
  • Organization City
    THE WOODLANDS
  • Organization State
    TX
  • Organization Country
    UNITED STATES
  • Organization Zip Code
    77381
  • Organization District
    UNITED STATES